Search Search
User Profile
Change
Select your user profile
Article

Hematopathology IHC/ISH solutions

Driving diagnostic certainty with Hematopathology IHC/ISH solutions

Hematological cancers vary significantly in both prognosis and aggressiveness, demonstrating a need for tools that assist pathologists in making confident diagnoses and helping to inform clinical decisions.1,2,3 We offer more than 60 cornerstone and novel ready-to-use IHC antibodies and ISH probes, which aid in diagnostics of lymphoma, leukemia, myeloma and other hematopoietic malignancies.

The robust and novel assays are supported by the innovative detection chemistry to deliver the high sensitivity and specificity you need from your assays. The ready-to-use reagents on the fully automated BenchMark IHC/ISH instruments, backed with workflow solutions, help reducing the time-to-results and resources needed with manual or semi-automated systems.

Related portfolios

Contact us

Featured assays

...
    ...

    You might be interested in

    ...
      ...

      References

      1. Tilly H, Gomes da Silva M, Violo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreudschuh M, Ladetto M. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Haematological Malignancies, Vol 26:S5, 2015.
      2. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamo A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of Oncology, Vol 27:12, 2016.
      3. Zucca E, Arcaini L, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Vol 31:1. 2020.